Technical Analysis for THAR - Tharimmune, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Calm After Storm | Range Contraction | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
50 DMA Support | Bullish | -5.61% | |
MACD Bullish Centerline Cross | Bullish | -5.61% | |
Slingshot Bullish | Bullish Swing Setup | -5.61% | |
Wide Bands | Range Expansion | -5.61% | |
Upper Bollinger Band Touch | Strength | -5.61% |
Alert | Time |
---|---|
Upper Bollinger Band Resistance | about 23 hours ago |
Up 10% | about 23 hours ago |
Rose Above Upper Bollinger Band | 1 day ago |
Down 5% | 1 day ago |
Down 3% | 1 day ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/28/2024
Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against specified targets.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Immunology Solid Tumors Autoimmune Disease Antibodies Oncology Cancer Immunotherapy Antibody Hepatology Inflammatory Primary Biliary Cholangitis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Immunology Solid Tumors Autoimmune Disease Antibodies Oncology Cancer Immunotherapy Antibody Hepatology Inflammatory Primary Biliary Cholangitis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 101.25 |
52 Week Low | 1.835 |
Average Volume | 1,292,497 |
200-Day Moving Average | 4.34 |
50-Day Moving Average | 2.54 |
20-Day Moving Average | 2.21 |
10-Day Moving Average | 2.32 |
Average True Range | 0.54 |
RSI (14) | 55.75 |
ADX | 30.1 |
+DI | 55.91 |
-DI | 14.06 |
Chandelier Exit (Long, 3 ATRs) | 4.78 |
Chandelier Exit (Short, 3 ATRs) | 3.44 |
Upper Bollinger Bands | 2.96 |
Lower Bollinger Band | 1.45 |
Percent B (%b) | 0.82 |
BandWidth | 68.33 |
MACD Line | 0.04 |
MACD Signal Line | -0.08 |
MACD Histogram | 0.1172 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.47 | ||||
Resistance 3 (R3) | 3.54 | 3.36 | 3.34 | ||
Resistance 2 (R2) | 3.36 | 3.16 | 3.32 | 3.30 | |
Resistance 1 (R1) | 3.02 | 3.04 | 2.93 | 2.95 | 3.25 |
Pivot Point | 2.84 | 2.84 | 2.79 | 2.80 | 2.84 |
Support 1 (S1) | 2.50 | 2.64 | 2.41 | 2.43 | 2.13 |
Support 2 (S2) | 2.32 | 2.52 | 2.28 | 2.08 | |
Support 3 (S3) | 1.98 | 2.32 | 2.04 | ||
Support 4 (S4) | 1.91 |